GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier(TM), a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French “Conformite Europeenne”) certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner…

Read more from the original source: 
New Type 2 Diabetes And Obesity Treatment Approved – EndoBarrier Receives European CE Mark

Related posts:

1. Gore Receives European CE Mark Approval For Next Generation Conformable GORE TAG(R) Thoracic EndoprosthesisW.L. Gore & Associates (Gore) announced that it has received European CE Mark approval for the next generation GORE TAG® Thoracic Endoprosthesis. ...
2. Type 2 Diabetes Gene Predisposes Children To ObesityPediatric researchers have found that a gene already implicated in the development of type 2 diabetes in adults also raises the risk of being overweight during childhood. The finding sheds...
3. FDA Approved Drug May Slow Beta Cell Destruction In Type 1 Diabetes PatientsNew findings by UT Southwestern researchers suggest that a drug already used to treat autoimmune disorders might also help slow the destruction of insulin-producing cells in patients recently diagnosed with...
4. European Society Of Cardiology To Give Talks On Diabetes In Three Cities In ChinaAs a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of...
5. European Society Of Cardiology To Give Talks On Diabetes In Three Cities In ChinaAs a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of...
6. Echo Therapeutics Announces Positive Results Of A Clinical Study Testing Symphony(TM) TCGM System In Patients With Type 1 And Type 2 DiabetesEcho Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System...
7. Surgery Recognized As Effective Treatment For Selected Type 2 Diabetes PatientsA first-of-its-kind consensus statement by 50 medical experts from around the world has pronounced surgery to be a legitimate and effective treatment for type 2 diabetes, bringing the procedure a...
8. KineMed Receives An Investigator-Initiated Study Grant To Further Explore Mechanism(s) Of Action Associated With Welchol® In Type 2 Diabetes MelliKineMed, Inc., a translational and personalized medicine development company, announced today that the company has received an investigator initiated study grant from Daiichi Sankyo, Inc. to conduct a clinical study...
9. Two Thirds Of Brits Do Not Know The Difference Between Type 1 And Type 2 DiabetesNew research out today reveals that less than a third of UK residents (30 per cent) know of type 1 diabetes with a further 59 per cent confusing the autoimmune...
10. Natural Remedies for the Treatment of Type 2 DiabetesAs  Dr Patrick Higgins of Toronto might tell you, type II diabetes is the more common of the two types of diabetes. With this type, which almost ninety percent of...
11. Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Type 1 Gaucher DiseaseShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme...
12. Cardiovascular Risk In Youth With Type 1 Diabetes Linked Primarily To Insulin ResistanceAccording to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), youth with type 1 diabetes have now been found to have...
13. Novartis Receives Approval In The European Union For Onbrez® Breezhaler®, A New Once-daily Bronchodilator For Patients With COPDNovartis announced that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of...
14. What Are The Different Type Of Diabetes?Diabetes mellitus mainly comes when pancreas does not produce in sufficient amounts or any of hormone insulin or when insulin is generated that does not perform out efficiently....
15. Ellipse Technologies, Inc. Receives CE Mark Clearance For The MAGECTM System For The Treatment Of Spinal ScoliosisEllipse Technologies, Inc. ("Ellipse") announced today it has received CE Mark (Conformité Européenne) for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is...